Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

WideCells moves a step closer to becoming an end-to-end stem cell service company following green light from UK regulator

The official approval allows the group, under its brand name BabyCells, to offer umbilical cord blood and tissue storage services to clients in the UK and Europe
man at a micrscope
The company owns a state-of-the-art storage facility in Manchester

WideCells Group PLC (LON:WDC) has taken a “significant step” towards becoming an end-to-end stem cell service company, according to chief executive João Andrade.

His comments followed the grant of a licence by the UK's Human Tissue Authority, which allows the company import, export, process, store and distribute for treatment umbilical cord blood and tissue.

WATCH: All WideCells divisions to start generating revenues after UK regulator approval

What in practice this official sanction does is allow the group, under its brand name BabyCells, to offer umbilical cord blood and tissue storage services to clients in the UK and Europe.

BabyCells service 

The company said the BabyCells service will be charged at around £2,000 per sample for one year's storage, with recurring storage revenues priced at £50-£75 a year thereafter.

Clients will be offered one year's stem cell insurance cover provided by the firm’s CellPlan division,” said CEO Andrade.

“This licence enables us to leverage further our significant industry contacts and market presence to position our state-of-the-art facility in Manchester as a leading stem cell storage bank.

“The group is now positioned to focus on revenue generation from all three of our divisions."

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use